Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSONG.L Regulatory News (SONG)

  • There is currently no data for SONG

Dividend Declaration

8 Feb 2022 07:00

RNS Number : 9470A
Hipgnosis Songs Fund Limited
08 February 2022
 

LEI: 213800XJIPNDVKXMOC11

8 February 2022

 

HIPGNOSIS SONGS FUND LIMITED

 (the "Company" or "Hipgnosis")

 

Interim Dividend Announcement

 

The Board of Hipgnosis, the first UK listed investment company offering investors a pure-play exposure to songs and associated musical intellectual property rights, and its Investment Adviser, Hipgnosis Song Management Limited (formerly The Family (Music) Limited), are pleased to announce the Company's interim dividend (the 'Dividend') for the period from 1 October to 31 December 2021 in respect of the Ordinary shares.

 

The Dividend of 1.3125 pence per Ordinary Share will be payable to Shareholders on the register as at 18 February 2022 with an associated ex-dividend date of 17 February 2022 and a payment date of 15 March 2022.

 

 

For further information, please contact:

 

Hipgnosis Song Management Limited (formerly The Family (Music) Limited)

Merck Mercuriadis

 

 

Tel: +44 (0)1481 742742

Singer Capital Markets - Joint Corporate Broker

James Maxwell / James Moat / Amanda Gray (Corporate Finance)

Alan Geeves / James Waterlow / Sam Greatrex (Sales)

 

Tel: +44 (0)20 7496 3000

J.P. Morgan Cazenove - Joint Corporate Broker

William Simmonds / Jérémie Birnbaum (Corporate Finance)

James Bouverat (Sales)

 

Tel: +44 (0)20 7742 4000

RBC Capital Markets - Joint Corporate Broker

Elliot Thomas / Max Avison / Lauren Davies (Corporate Finance)

Lisa Tugwell (Sales)

 

Tel: +44 (0)20 7635 4000

Ocorian - Company Secretary & Administrator

Lorna Zimny

 

Tel: +44 (0) 28 9693 0222

The Outside Organisation

Alan Edwards / Nick Caley

Tel: +44 (0)7711 081 843

 

FTI Consulting

Neil Doyle/ Paul Harris/ Laura Ewart

 

 

Tel: +44 (0)7771 978220; +44 (0)7809 411882; +44 (0)7761 332646

 

All US music publicity enquiries

Fran Defeo

Tel: +1 917 767 5255

 

 

 

 

NOTES TO EDITORS

About Hipgnosis Songs Fund Limited

(www.hipgnosissongs.com)

Hipgnosis, which was founded by Merck Mercuriadis, is a Guernsey registered investment company established to offer investors a pure-play exposure to songs and associated musical intellectual property rights. The Company has raised a total of almost £1.3 billion (gross equity capital) through its Initial Public Offering on 11 July 2018, and subsequent issues in April 2019, August 2019, October 2019, July 2020, September 2020, February 2021 and July 2021. In September 2019, Hipgnosis transferred its entire issued share capital to the Premium listing segment of the Official List of the FCA and to the London Stock Exchange's Premium segment of the Main Market, and in March 2020 became a constituent of the FTSE 250 Index. Since April 2021, the Company has been resident in the UK for tax purposes and is recognised as an investment trust under applicable HMRC regulations.

About Hipgnosis Song Management Limited (formerly The Family (Music) Limited)

 

The Company's Investment Adviser is Hipgnosis Song Management Limited, which was founded by Merck Mercuriadis, former manager of globally successful recording artists, such as Elton John, Guns N' Roses, Morrissey, Iron Maiden and Beyoncé, and hit songwriters such as Diane Warren, Justin Tranter and The-Dream, and former CEO of The Sanctuary Group plc. The Investment Adviser has assembled an Advisory Board of highly successful music industry experts which include award winning members of the artist, songwriter, publishing, legal, financial, recorded music and music management communities, all with in-depth knowledge of music publishing. Members of Hipgnosis Song Management Limited Advisory Board include Nile Rodgers, The-Dream, Giorgio Tuinfort, Starrah, David A. Stewart, Poo Bear, Bill Leibowitz, Ian Montone and Rodney Jerkins.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DIVTRMPTMTBMBRT
Date   Source Headline
19th Apr 202412:02 pmRNSForm 8.3 - Hipgnosis Songs Fund Limited
19th Apr 202411:38 amRNSForm 8.5 (EPT/NON-RI)-Hipgnosis Songs Fund Limited
19th Apr 202411:30 amRNSForm 8.5 (EPT/RI)-Hipgnosis Songs Fund Limited
19th Apr 202411:20 amRNSForm 8.3 - Hipgnosis Songs Fund Limited
19th Apr 202410:38 amRNSForm 8.5 (EPT/RI)
19th Apr 202410:38 amRNSForm 8.3 - Hipgnosis Songs Fund Limited
18th Apr 20243:40 pmRNSForm 8.3 - Hipgnosis Songs Fund Limited
18th Apr 20241:17 pmRNSForm 8.3 - Hipgnosis Songs Fund Limited
18th Apr 202411:14 amRNSForm 8.3 - Hipgnosis Songs Fund Limited
18th Apr 202410:26 amRNSForm 8.3 - Hipgnosis Songs Fund Limited
18th Apr 20247:00 amRNSRECOMMENDED CASH OFFER FOR HIPGNOSIS
15th Apr 20247:00 amRNSChange to Director roles and responsibilities
28th Mar 20249:02 amRNSFinal Due Diligence Findings
18th Mar 20247:00 amRNSAmendment to Operative Net Asset Value
4th Mar 20249:27 amRNSUpdate on Due Diligence, Valuation and NAV
4th Mar 20247:00 amRNSUpdate on Due Diligence, Valuation and NAV
26th Feb 20247:00 amRNSLitigation update
19th Feb 20247:00 amRNSLitigation Update
7th Feb 202412:35 pmRNSResult of Extraordinary General Meeting (“EGM”)
5th Feb 20247:00 amRNSLitigation Update
23rd Jan 20247:00 amRNSPublication of Circular/Update to Strategic Review
18th Jan 20247:00 amRNSProposed Change to Articles of the Company
11th Jan 20247:00 amRNSDirectorate Change
4th Jan 20243:26 pmRNSHolding(s) in Company
21st Dec 20237:00 amRNSInterim results to 30 September 2023
20th Dec 20237:00 amRNSChange of Auditor
19th Dec 20237:00 amRNSDelay to publication of interim results
15th Dec 20237:00 amRNSDirectorate Change
11th Dec 20237:00 amRNSAsset sale, adviser appointment, notice of results
28th Nov 202312:52 pmRNSHolding(s) in Company
23rd Nov 20237:00 amRNSStrategic Review and Company Update
20th Nov 20237:00 amRNSDirector/PDMR Shareholding
7th Nov 20237:00 amRNSDirectorate Changes
6th Nov 20237:00 amRNSUpdate on dividend intentions
26th Oct 202311:20 amRNSResult of AGM and EGM
25th Oct 20234:00 pmRNSDirectorate Changes, withdrawal of AGM Resolutions
24th Oct 20237:00 amRNSConclusion of Go-Shop process
19th Oct 20237:00 amRNSInitiation of Strategic Review, update on RCF
17th Oct 202312:22 pmRNSHolding(s) in Company
17th Oct 202312:21 pmRNSHolding(s) in Company
17th Oct 202312:18 pmRNSHolding(s) in Company
16th Oct 20236:17 pmRNSUpdate on CRB III and dividend payment
16th Oct 20237:13 amRNSUpdate on CRB III impact and dividend payment
28th Sep 202311:07 amRNSPublication of Circular and Notice of AGM & EGM
25th Sep 20232:41 pmRNSHolding(s) in Company
22nd Sep 202310:49 amRNSHolding(s) in Company
21st Sep 20237:00 amRNSDividend Declaration
20th Sep 20237:00 amRNSHolding(s) in Company
14th Sep 20237:00 amRNSAsset sales to fund buy backs and reduce debt
14th Aug 202312:29 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.